Department of Oncology, Weifang People's Hospital, Weifang, China.
Department of Pharmacology, School of Basic Medicine, Qingdao University, Qingdao, China.
Immunotherapy. 2024;16(16-17):1015-1019. doi: 10.1080/1750743X.2024.2394405. Epub 2024 Sep 11.
Gastric cancer remains a considerable global health burden, with limited treatment options available for advanced cases, especially for superaged patients. Cadonilimab, a first-in-class bi-specific antibody (BsAb), offer a promising immunotherapy approach by targeting PD-1/CTLA-4 simultaneously. Herein, we present a case report of an 85-year-old patient with HER2-negative advanced gastric cancer who received first-line treatment with cadonilimab combined with chemotherapy, but cadonilimab was discontinued due to the observation of immune-related pneumonitis during treatment. Despite these changes, the patient still exhibited a stable disease condition for a year until now. This case report highlights the potential of cadonilimab in the treatment of superaged patients with advanced gastric cancer, while the efficacy and safety of it need to be further evaluated.
胃癌仍然是一个相当大的全球健康负担，对于晚期病例，特别是对于超高龄患者，治疗选择有限。Cadonilimab 是一种首创的双特异性抗体（BsAb），通过同时靶向 PD-1/CTLA-4 提供了一种有前途的免疫治疗方法。在此，我们报告了一例 85 岁 HER2 阴性晚期胃癌患者的病例，该患者接受了 cadonilimab 联合化疗的一线治疗，但由于在治疗过程中观察到免疫相关肺炎，cadonilimab 被停用。尽管发生了这些变化，该患者的疾病状况仍保持稳定，至今已一年。本病例报告强调了 cadonilimab 在治疗超高龄晚期胃癌患者中的潜力，但其疗效和安全性仍需进一步评估。
